Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in @entity1 with Unresectable XXXX .

@entity1 @entity6288 @entity14 @entity121 @entity1349
BACKGROUND: Skeletal muscle depletion ( @entity6288 ) is closely associated with limited physical ability and high mortality. This study evaluated the prognostic significance of skeletal muscle status before and after chemotherapy in @entity1 with unresectable @entity14 ( @entity14 ). METHODS: We conducted a retrospective analysis of 215 consecutive @entity1 with unresectable @entity14 who underwent systemic chemotherapy. Skeletal muscle cross-sectional area was measured by computed tomography. We evaluated the prognostic value of skeletal muscle mass before chemotherapy and the rate of skeletal muscle change in cross-sectional area after chemotherapy. RESULTS: One-hundred-eighty-two @entity1 met our inclusion criteria. There were no significant differences in progression-free survival (PFS) or @entity1349 ( @entity1349 ) associated with skeletal muscle mass before chemotherapy. However, 22 @entity1 with skeletal @entity121 (>5%) after chemotherapy showed significantly shorter PFS and @entity1349 compared with those without skeletal @entity121 (PFS, log-rank p = 0.029; @entity1349 , log-rank p = 0.009). Multivariate Cox regression analysis revealed that skeletal @entity121 after chemotherapy (hazard ratio, 2.079; 95% confidence interval, 1.194-3.619; p = 0.010) was independently associated with @entity1349 . CONCLUSIONS: Skeletal @entity121 after chemotherapy was an independent, negative prognostic factor in unresectable @entity14 .
